

Published in final edited form as:

Tetrahedron. 2009 February 14; 65(7): . doi:10.1016/j.tet.2008.11.085.

Synthesis, Redox Properties, and Conformational Analysis of Vicinal Disulfide Ring Mimics

Erik L. Ruggles¹, P. Bruce Decker², and Robert J. Hondal^{*,1}

Department of Biochemistry, 89 Beaumont Ave., Given Building, University of Vermont, Burlington VT 05405 U.S.A.

Abstract

A vicinal disulfide ring (VDR) results from disulfide bond formation between two adjacent cysteine residues. This 8-membered ring is a rare motif in protein structures and is functionally important to those few proteins that possess it. This article focuses on the construction of strained and unstrained VDR mimics, discernment of the preferred conformation of these mimics, and the determination of their respective disulfide redox potentials.

Keywords

cyclocystine; dithiocine; dithiazacanonones; eight-membered ring; vicinal cysteines; thiol disulfide redox

1.0 Introduction

1.1 VDR biological function

A vicinal disulfide ring (VDR; **1**) is an eight-membered ring structure that occurs as a result of disulfide bond formation between vicinal cysteines and is a very rare occurrence in protein structures (Figure 1). In the most current search for this structure in the Brookhaven Protein Data Bank (PDB), Perczel and coworkers found 31 occurrences out of ca. ~28,000 deposited protein structures.¹ Given its rare occurrence in the PDB, this ring system must have a unique structural/functional assignment where it is found. In the Janus-faced atracotoxins mutation of this motif to a vicinal serine pair resulted in no change in tertiary geometry of the protein, however the mutant was devoid of toxicity.² In the case of methanol dehydrogenase, reduction of the VDR is accompanied by complete loss of enzymatic activity. Here it has been proposed that the ring aids in either electron transfer or conformational rigidity of the protein during substrate binding.^{3,4} We believe one very important role for this ring system is to act as a conformational switch and it is able to do so in two ways. First it may act as a conformational switch by lowering the *trans/cis* isomerization barrier of the peptide backbone. Several NMR studies of model peptides containing this ring have demonstrated that an 8-membered ring formed by a vicinal

© 2008 Elsevier Ltd. All rights reserved.

*Corresponding Author: Department of Biochemistry, B413 Given Building, University of Vermont, 89 Beaumont Ave., Burlington, VT 05405, USA. Telephone: (802) 656-8282; Fax: (802) 656-8220; Robert.Hondal@uvm.edu.

¹Department of Biochemistry, University of Vermont, Burlington, VT 05405.

²Department of Chemistry, University of Vermont, Burlington, VT 05405.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

disulfide is in dynamic equilibrium between *trans* and *cis* conformations about the amide bond of the ring and that conversion from the *trans* form to the *cis* form would dramatically alter protein topology.^{5,6} Such a process is proposed to occur in the nicotinic acetylcholine receptor's (nAChR) binding site. Upon binding with acetylcholine, or other agonists, the ring undergoes a conformational change that makes it two orders of magnitude more resistant to reduction.⁷ This type of conformational regulation has also been proposed for the vicinal disulfide ring of cytochrome *C* from *Utricularia*.⁸ Second, it may act as a redox conformational switch. Examples of this type of switch have been shown in human RNase H1,⁹ and the hSH3^N domain of the adhesion and degranulating promoting adapter protein (ADAP).¹⁰ The mechanism by which the switch acts is through the change in peptide backbone conformation that is observed on going from the reduced state to the oxidized state. Upon oxidation of vicinal cysteines, formation of the 8-membered ring has the effect of constraining backbone torsion angles ϕ , ψ , and ω , similar to the effect that proline (a 5-membered ring) has on the backbone.^{11,12} This change in backbone conformation is rather dramatic as has been observed in the case of the hSH3^N domain of ADAP. In both RNase H1 and the hSH3^N domain of ADAP, it has been proposed that this motif acts as a cellular redox state sensor, as oxidation of the vicinal cysteine pair in RNase H1 leads to inactivation of the enzyme.⁹ The redox potential of the vicinal cysteine pair for the hSH3^N domain has been determined to be -228 mV.¹⁰ This value is within the range of disulfide redox potentials found in proteins, but is near the oxidizing end of the scale. We posit that the relative instability of this particular disulfide bond is by design and is due to the strained nature of the ring. The strain in the ring is due to the distorted *trans* conformation that the ring adopts as determined by NMR spectroscopy. This next point is addressed in the following section.

1.2 VDR conformation

When the field of peptide structure was relatively new, it was predicted by Chandrasekaran and Balasubramanian that a VDR dipeptide should have a nonplanar *cis* geometry with a dihedral angle (ω) of -12° .¹³ The dihedral angle for the cyclic disulfide *L*-cysteinyl-*L*-cysteine was later experimentally determined to be -7° by X-ray crystallography.^{14,15} Similar *cis* ω -dihedral angles were also observed in the bicyclic diketopiperazine ring system of cyclo-*L*-cystine.^{16,17} A NMR study of VDR **6** in which R2 is replaced with O^tBu and the acetyl group replaced with Boc (Figure 1) found evidence for two conformers in chloroform, both with *cis* amide geometry, in agreement with the earlier crystallographic and NMR studies.¹⁸ However, if the amino-terminus in **6** is replaced with gem-dimethyl substituents, two conformations are observed both with *trans* amide geometries by NMR and X-ray crystallography.¹⁹ Another solid state and solution conformational study revealed that a *trans* conformer was observed if the stereochemistry of the carbon α to the ring amide nitrogen is inverted, as is in the case of phenylacetyl-*L*-cysteinyl-*D*-penicillamine.²⁰ When VDR **6** was placed in the context of a heptamer peptide, the conformer population that was *cis* was found to be $70 \pm 5\%$ as determined by NMR spectroscopy.²¹ However, when VDR **6** was part of the pentameric peptide TCCPD, found in the nAChR, both *cis* and *trans* conformers of the VDR were found to exist in solution and these conformers were found to interconvert, lending support for the idea that the ring motif could act as a protein conformational regulatory switch.⁷ A NMR study of the isolated dipeptide **6** done in aqueous solution revealed the presence of two *trans* conformers (designated as *T*- and *T'*-) and two *cis* conformers (designated as *C*+ and *C*-), with *trans* and *cis* isomers being in equilibrium with a ratio of $\sim 60:40$, with *trans* being slightly favored.⁵

In contrast to the model studies of small peptides above, a complete analysis of the PDB performed by Perczel and coworkers of the 31 deposited structures containing a VDR showed that all of the ring structures were in a strained, distorted *trans* conformation with

average values of ω lying between 161° and -172° with deviations from 180° as large as 44° being observed.¹ This discrepancy may be explained by the dynamic nature of the VDR not properly being accounted for in X-ray protein structures in particular. In a NMR study of the bass hepcidin structure it was noted that the most flexible region of the protein was the area containing the VDR.²² Peptide bonds prefer a *trans* conformation, with a torsion angle of 180° , so that the nitrogen lone-pair can have maximal delocalization into the π -system. This also minimizes steric repulsions from large peptidyl side-chains. However, small rings that have a central bond with restricted rotation will prefer to adopt a *cis* conformation to minimize ring strain. These disparate facts raise the question of what the preferred amide geometry of a VDR will be. This point was first raised by North, whose inspection of molecular models of smaller amide rings (less than 8 atoms) closed by a disulfide were found to have exclusively *cis* amide geometry (analogous to cycloalkenes), while larger rings (more than 8 atoms) had *trans* amide geometry.²³ The transition point between amide-disulfide ring systems with all *cis* geometry and all *trans* geometry was 8 atoms. These 8-membered ring systems (VDRs) seem to be a special case as they can adopt either geometry and can oscillate between the two types in solution. This ability to easily switch between *cis* and *trans* amide geometries may make a VDR a good “molecular switch”,²⁴ regulating the conformation of proteins as has been proposed for the nAChR.^{8,25}

Multiple amide (*trans/cis*) and disulfide ($+/-90^\circ$) conformations are energetically feasible in the unique case of a VDR. An all carbon analogue of a VDR that could be used as a point of comparison is cyclooctene. Both are 8-membered ring systems with a central bond that has some type of unsaturation; the element of unsaturation in cyclooctene is a carbon-carbon double bond, while a VDR contains an amide bond with only 40% double bond character. While both a VDR and cyclooctene are similar in having restricted rotation about a central bond and ring size, there are significant conformational differences. For cyclooctene, the *cis* isomer is more energetically stable than the *trans* as a result of the ring strain required to incorporate a *trans* double bond. This ring strain is demonstrated by the higher ΔH_{H_2} of *trans*-cyclooctene (34.4 kcal/mol) compared to the *cis* isomer (23.0 kcal/mol).²⁶ By contrast and as noted above, a VDR has a fluxional nature that permits both *cis* and *trans* conformers due to: (i) the longer carbon-sulfur and sulfur-sulfur bonds, which makes this 8-membered ring larger and more flexible than its all carbon analogue (ii) the amide bond having only partial double bond character allows for rotation about the C-N axis.

Since a VDR is a potential regulatory conformational switch in proteins, it would be useful to understand the factors that potentiate amide geometry in this system. Studies by North and coworkers found that cyclo-[(*R*)-cysteinyl-(*R*)-penicillamine] adopts a *cis* conformation, while a *trans* conformation is observed upon changing the penicillamine stereochemistry from *R* to *S*.^{23,27} We have confirmed this observation by constructing cyclo-[*L*-Cys-*D*-Cys]. Similar conformational studies showed that switching the stereochemistry of the C_α on the N-terminal Cys results in a strained *trans* conformation of the molecule with no *cis* conformers present (data not shown). Thus both stereochemistry and substituents about the ring effect amide geometry of a VDR.

As we were interested in VDRs in the context of a redox regulatory switch, we wanted to determine the redox potential of a *cis* VDR and a *trans* VDR. We wanted to mimic the situation in proteins, thus we avoided changing the stereochemistry of the α -carbon and focused instead on changing the properties of the amide bond by *N*-methylation. It has been previously established that *N*-methylation of the amide bond increases the population of the *cis* conformer in peptides.²⁸ Construction of *cis* and *trans* VDRs would then allow us to assess how VDR conformation affects the redox potential of the disulfide-bond, and explore our *VDR hypothesis* that a VDR with a *cisoid* peptide bond will be a weaker oxidant than a

VDR with a *transoid* peptide bond. Correspondingly, this means that the dithiol with a *cisoid* peptide bond will be the stronger reductant.

2.0 Results and Discussion

2.1 Determination of redox potentials

In order to test our hypothesis, variants of the VDR are needed with different elements of rigidity (2–7, Figure 1). Fully *cis* or *trans* dithiocines **2** and **3** mimic opposite ends of the amide rotational spectrum. Dithiazacanones **4** and **5** are not as rigid as compared to **2** and **3** due to the replacement of the central alkene with an amide bond. North has previously reported that amide **4** exists exclusively in a *trans* conformation.²⁹ While *N*-Me amide **5** is unknown in the literature it is predisposed for a *cis* conformation as a result of steric interactions.²⁸ Dithiazacanones **4** and **5** are the “parent” compounds for VDR mimics as they contain no appendages that would affect the conformation of the ring. Disulfides **6** and **7** however are dipeptides that have substituents on C_α and represent a minimalist VDR. Compound **6** was constructed by Leo and coworkers and displayed 4 major conformations, two being *cis* and two *trans*, with a *trans/cis* ratio of 60:40.⁵ Compound **7** has not been reported in the literature, but *N*-methylation should favor a *cis* amide orientation as is the case in **5**.²⁸ The redox potentials are determined by equilibrium thiol-disulfide exchange, with the varying concentrations of reduced and oxidized forms monitored by ¹H-NMR (Figure 2).^{30,31} Employment of oxidized or reduced butane dithiol (**BDT_{ox}** and **BDT_{red}**, respectively), a species of known redox potential E_{0(BDT)}, allows for the redox potential of the VDR mimics to be determined by equations 1 and 2.

$$K_{\text{ox}}^{-1} = K_{\text{red}} = \frac{[\mathbf{8}][\text{BDT}_{\text{ox}}]}{[\mathbf{2}][\text{BDT}_{\text{red}}]} \quad (1)$$

$$E_0 = E_{0(\text{BDT})} - 0.031 \log(K_{\text{ox}}) \quad (2)$$

2.2 Synthesis, conformation, and redox potential of dithiocines **2** and **3**

Our earlier communication involves the synthesis and redox properties of dithiocines **2** and **3**.³¹ The dithiocine sulfhydryl precursors were readily available from diol intermediates **11** (Scheme 1) and **15** upon Mitsunobo thioesterification and hydrolysis (Scheme 1).^{32,33} Dithiocine **2** was isolated in good yield upon CsF-celite mediated oxidation.³⁴ However, dithiocine **3** was never isolated even under dilute conditions with the cyclic dimer **18** predominating. The redox data (Table 1) supports our hypothesis by displaying a monomeric redox potential for *cis*-olefin **2** (–318 mV) and a dimeric redox potential for the *trans*-olefin **3** (–329 mV).³¹ The inability to observe a monomeric potential for the *trans* mimic and its propensity to dimerize suggests a strong oxidative potential. The ring-strain necessary to incorporate the *trans*-olefin is represented by a fragile disulfide-bond and results in an inability to form the cyclic monomer. Thus the *cis*-dithiocine is more stable than *trans*, making **3** a much stronger oxidant in comparison to **2**. The dithiol of **2** is thus a very strong reductant. These initial results supported our VDR hypothesis.

2.3 Synthesis, conformation, and redox potential of dithiazacanones **4** and **5**

Construction of dithiazacanones **4** and **5** begins with sulfhydryl trityl protection of both acid **19** and amine **20** (Scheme 2).^{29,35} Standard amide coupling provides common intermediate **23**.^{29,36} Dithiol deprotection,³⁷ followed by oxidation provides **4** in low yield along with two unidentified oligomeric products.³⁴ Amide *N*-methylation of **23** generates **24** in mediocre yield,³⁸ after which analogous sulfhydryl deprotection and oxidation affords

5.^{34,37} Despite the fact that the dithiazacanones are similar in structure they differ in conformation (Figure 3). Prior to this report, North observed that disulfide **4** existed in one *trans*-conformation.²⁹ However here we have observed that VDR **4** populates two *trans*-conformations with a ratio of 1.7:1.0. In support of our result, after determining the separate spin-systems in VDR **4** by COSY NMR, ROESY experiments showed magnetization transfer between the two species specifically between the conformers C_{αN} protons and C_{βC=O} protons. This result supports the existence of two conformers (Supporting Information). The *trans* amide bond geometry was determined at 5 °C by ROESY signals between the amide proton and C_{αC=O}, C_{βC=O}, and C_{βN} protons. As a result of the strong ROESY signals between the amide proton and axial C_{αC=O} and C_{βN} protons, a *cis*-amide conformation can be ruled out. Disulfide **5** exists in one predominating conformation, however the amide geometry is now *cis*. Here, TOCSY NMR determined the different spin-systems within VDR **5** and ROESY signals showed a strong through-space interaction between the C_{αN} and C_{βC=O} protons as well as a weaker C_{αN} and C_{αC=O} contact. These through space interactions would not be possible if the amide geometry was *trans*. A much weaker contact between the *N*-Me and C_{βN} protons was also observed. Additional support of a *cis*-amide geometry is demonstrated by this species flexibility at room temperature, reminiscent of dithiocine **2**.³¹ This flexibility was demonstrated by ¹H-NMR coalescence experiments (Supporting Information). The observed redox potentials (Table 1), determined by equations 1 and 2, for both **4** (−278 mV) and **5** (−320 mV) are in support of the VDR hypothesis. Amide **4** exists in a *trans* conformation and as a result of the ring strain needed to accommodate this geometry, it is the stronger oxidant when compared to **5**. The *trans* geometry of the precursor dithiol of **4** disfavors disulfide bond formation since the sulfur atoms are distant, *e.g.*, not close to each other in space. Amide **5** is the weaker oxidant as a result of the *cis* amide bond relieving ring strain and thus stabilizing the disulfide. In this case, the precursor dithiol of **5** most likely has a significant population of the *cis* conformer, which brings the sulfur atoms closer in space and favors intramolecular disulfide bond formation. This fact makes the dithiol form of **5** a good reductant. These redox data for the dithiazacanone VDR mimics supports our VDR hypothesis since the more strained system is the stronger oxidant.

The redox potential of disulfide **4** (−278 mV) is particularly interesting in light of the determined redox potential of the single vicinal disulfide bond of the hSH3^N domain in ADAP being −228 mV.¹⁰ Disulfide **4** has the highest redox potential (strongest oxidant) of all the mimics in Table 1. Since both North and ourselves have demonstrated that the amide bond geometry is in an all *trans* configuration, it is expected to be the most strained of the amide-containing disulfides that are in this study. While it is not a perfect mimic of the strained disulfide bond within the hSH3^N domain of ADAP, the results in Table 1 clearly demonstrate how straining the amide bond within a VDR affects the redox potential of the disulfide bond. Clearly a disulfide bond can be more strained in the context of a folded domain such as that found in the hSH3^N domain of ADAP compared to when the disulfide bond is isolated and brought out of its protein context, as is disulfide **4**. This is the first study that we are aware of that quantitates redox potentials of vicinal disulfide bonds and makes a comparison to strain in the peptide torsion angle.

2.4 Synthesis, conformation, and redox potential of dipeptides **6** and **7**

Construction of the VDR dipeptides begins with fashioning **6**.⁵ Amide coupling of **27** and **28** provides **29** in good yield (Scheme 3).³⁶ Sulfhydryl deprotection and oxidation affords **6** in modest isolated yield.^{34,37} Construction of **7** was much more labor intensive. Amine methylation proved difficult under a variety of conditions. Fortunately *N*-methylation was achieved via oxazolidinone intermediate **32**.^{39,40} The oxazolidinone ring opens upon treatment with TES/TFA to provide *N*-Me cysteine **33**, whose sulfhydryl is StBu

protected.⁴¹ Methyl esterification and Fmoc deprotection ensues,^{42,43} followed by amide coupling with acid **27** to generate dipeptide **35**.⁴⁴ The StBu-group is removed,⁴⁵ and after treatment with DTNP cyclizes spontaneously under acidic conditions to produce *N*-Me VDR **7**.⁴⁶ While the true pathway for this cyclization is currently under investigation, a possible mechanism employs an addition-elimination sequence (Scheme 4). First the trityl-protected sulfur atom is deprotected which generates a free sulfhydryl. The unmasked thiol now attacks the vicinal cysteinyl sulfur atom, whose electrophilicity is enhanced by the Npys group, expelling pyridinyl-thione. The attacking sulfhydryl's proton is subsequently scavenged. Problematic to this step was also the production of diNpys-protected dipeptide **37**, resultant from DTNP protection of both sulfur atoms. Compound **37** can also be transformed into VDR **7** upon treatment with dithiothreitol in similar yield.⁴⁵ As with the dithiazacanones, VDR **6** and **7** are similar in structure but not in conformation (Figure 4). VDR **6** exists as a mixture of four detectable interconverting *cisoid* (*C+*:*C*- 36:5) and *transoid* (*T*-:*T*'-42:17) amide conformers with *transoid* being preferred in accordance with what was observed prior by Leo and coworkers (Figure 4, *trans/cis* 59:41).⁵ VDR **7** exists in one major conformation that is *cisoid* in nature (Figure 4). These conformations were determined in a similar manner as dithiazacanone VDRs **4** and **5**. The observed redox potentials, determined by equations 1 and 2, for both **6** (-311 mV) and **7** (-363 mV) are in support of our hypothesis (Table 1). While both VDR dipeptides are flexible the *N*-Me VDR **7** exists preferentially in a *cisoid* confirmation while **6** is primarily *transoid*. In accord with prior results VDR **6** is a stronger oxidant, when compared to **7**, as a result of a weak disulfide-bond that is a consequence of incorporating a strained *transoid* amide geometry within the eight-membered ring. Conversely VDR **7** is a weaker oxidant, when compared to **6**, due to a stronger disulfide bond that is a result of a less strained *cisoid* ring system. These redox data for the dipeptide VDR mimics supports our hypothesis that dithiols that form *cisoid* 8-membered rings will be stronger reductants in comparison to dithiols that form *transoid* 8-membered rings. This means that a *transoid* VDR will be much more reactive towards thiol/disulfide exchange reactions and this enhanced reactivity could be harnessed by proteins for either catalytic or regulatory mechanisms. As noted above, all of the vicinal disulfide bonds in proteins so far have been found to be in such a strained state.

3.0 Summary

It is interesting to compare *trans*-dithiol **17** to that of a VDR found in proteins. When the central torsional angle is constrained to 180°, as is the case for **17**, intramolecular disulfide-bond formation is impossible. A disulfide-bond can form between nearest neighbors in peptidyl systems because the peptide bond is not as rigid as an olefin. This allows the central peptide bond of the VDR to adopt a strained *trans* geometry with the lone-pair of electrons on the nitrogen atom out of phase with the π system to varying degrees depending on the strain in the system. This amide bond strain allows disulfide bond formation to occur. Here we have demonstrated a correlation between amide strain and redox potential in a VDR. We also have demonstrated that this strain can be relieved, by forcing the VDR to adopt the *cis* conformation via *N*-methylation. A VDR with *cis* geometry is less strained as evidenced by the lower redox potentials of all of the VDR mimics in this study. While there are currently no known examples of a vicinal disulfide bond with *cis* amide geometry in the PDB, several redox enzymes contain a vicinal disulfide bond as part of their redox cycle and could use *cis* amide geometry to influence the redox potential of the VDR. Of particular interest to us are eukaryotic thioredoxin reductases that contain a C-terminal vicinal disulfide bond as part of their active site. The redox potential of the disulfide bond of the protein substrate (thioredoxin) is -270 mV.⁴⁷ Thus for efficient catalysis to occur, the redox potential of the vicinal disulfide bond of thioredoxin reductase should be more negative (more reducing) than this value. One way to achieve a lower redox potential would be to have the VDR of

thioredoxin reductase to adopt a *cis* amide geometry as shown here. A problem of having the VDR of a protein adopt a *cis* conformation is that it forces the peptide main chain to make a sharp turn, greatly altering protein topology and affecting protein function. This is most likely the cause of enzyme inactivation in RNase H1 upon oxidation of the vicinal cysteine pair. This problem is largely avoided in the cases of VDRs found in thioredoxin reductase and mercuric ion reductase since the vicinal cysteine pair occurs at the C-terminus of these enzymes, which would minimize the effect of the conformation on the rest of peptide chain. The conformation of the VDR of thioredoxin reductase is an area of intense research in our laboratory.

4.0 Experimental Details

4.1 Materials and methods

Reactions employed oven-dried glassware under argon unless otherwise noted. Argon was passed through a column of anhydrous CaSO₄ before use. Amino acids were purchased from Synpep Corp (Dublin, CA). All other chemicals were purchased from either Sigma-Aldrich (Milwaukee, WI) or Fisher Scientific (Pittsburgh, PA) and were used as received or purified by standard procedures.⁴⁸ Reactions were monitored by thin layer chromatography (TLC) using glass 0.25 mm silica gel plates with UV indicator. Flash chromatography was performed using columns packed with 230–400 mesh silica gel as a slurry in the elution solvent, unless otherwise noted. Gradient flash chromatography was conducted by adsorption of product mixtures on silica gel, packing onto fresh silica bed as a slurry in minimal hexanes, and eluting with a continuous gradient as noted in parentheses. Reverse-phase high performance liquid chromatography (RP-HPLC) was executed using a Shimadzu VP system with a Symmetry[®] C₁₈-5 μm column from Waters (4.6 × 150 mm) for analytical analysis and a SymmetryPrep[™] C₁₈-7 μm column from Waters (19 × 150 mm) for preparatory separation. Melting points were determined on a Meltemp apparatus and are uncorrected. Proton and carbon NMR data were obtained with a Varian or Bruker ARX 500 spectrometer at 20 °C unless otherwise noted. Chemical shifts for ¹H NMR and ¹³C NMR are reported in parts per million (ppm) relative to tetramethylsilane (δ = 7.24 ppm for ¹H NMR) or chloroform-*d* (δ = 77.0 ppm for ¹³C NMR) respectively. Infrared spectra were recorded with a Perkin-Elmer 2000 FT-IR spectrophotometer. Low resolution mass spectra were obtained with a Hewlett Packard 5988 GCMS. High resolution mass spectra were performed by the University of South Carolina Mass Spectrometry Laboratory. A Voyager-DE[™] PRO Workstation (Applied Biosystems) was used for mass spectral analysis of peptide samples.

4.2 Synthesis of dithiocine 2

4.2.1 7-Oxa-bicyclo[4.1.0]hept-3-ene (10)—In an air-dried flask 10.0 mL (106 mmol) 1,4-cyclohexadiene was added quickly to a stirring room temperature biphasic solution of 24.38 g (108 mmol) *m*-CPBA and 18.8 g (108 mmol) K₂HPO₄ in 762 mL DCM/H₂O (151:1). The reaction was stirred at room temperature for 18 hr. Quenched reaction with 200 mL aqueous NaHCO_{3(sat)} and layers were separated. DCM layer was washed once with 150 mL 5% aqueous Na₂SO₃ and once with 150 mL aqueous NaHCO_{3(sat)}. The combined aqueous washes were extracted two sequential times with 100 mL DCM. The DCM extractions were combined, dried over MgSO₄, filtered and concentrated to afford 9.56 g (94%) of **10** as a clear oil. R_f = 0.63 (1:2 hexanes/EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 5.42 (s, 2 H), 3.22 (s, 2 H), 2.56 (d, *J* = 14.0 Hz, 2 H), 2.43 (d, *J* = 13.5 Hz, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 121.5 (CH), 50.8 (CH), 24.9 (CH₂); Ir (neat) 1736 (m), 1422 (m), 1214 (m), 1021 (m) cm⁻¹; LRMS (EI) *m/z* 96.0 [(M⁺), calcd. for C₆H₈O: 96.0].⁴⁹

4.2.2 Hex-3-ene-1,6-diol (11)—In an air-dried flask 12 mL H₂SO₄ was added to a stirring room temperature solution of 6.17 g (64.2 mmol) epoxide **10** in 200 mL THF/H₂O (1:1). Upon complete addition the reaction was refluxed (oil-bath=85 °C) for 1 hr and then cooled to 0 °C. Over 30 min 14.4 g (67.4 mmol) NaIO₄ was added in three portions after which the reaction was stirred for 1.5 hr. A solution of 3.66 g (96.7 mmol) NaBH₄ in 15 mL H₂O was then added dropwise via addition funnel to the cold reaction. Upon complete addition the reaction was allowed to warm to room temperature and subsequently stirred for 30 min. After quenching with 100 mL aqueous NH₄Cl_(sat), the layers were separated and the aqueous was extracted three consecutive times with 100 mL DCM. The DCM extractions were combined, dried over MgSO₄, filtered and concentrated. The diol was purified after impregnation onto flash silica gel via gradient flash-chromatography (2:1 hexanes/EtOAc to 1:2 to EtOAc) to provide 3.55 g (48%) of **11** as a light yellow oil. R_f = 0.28 (1:2 hexanes/EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 5.50 (m, 2 H), 3.59 (t, *J* = 6.0 Hz, 4 H), 3.52 (br s, 2 H), 2.29 (q, *J* = 6.2 Hz, 4 H); ¹³C NMR (125 MHz, CDCl₃) δ 128.7 (CH), 61.5 (CH₂), 30.4 (CH₂); Ir (neat) (neat) 3376 (m), 3336 (m), 1740 (m), 1462 (m), 1350 (m), 1259 (m), 1042 (m) cm⁻¹; LRMS (EI) *m/z* 116.0 [(M+), calcd. for C₆H₁₂O₂: 116.0].⁵⁰

4.2.3 Thioacetic acid S-(6-acetylsulfanyl-(Z)-hex-3-enyl) ester (12)—To a chilled (0 °C) stirring solution of 13.5 g (51.4 mmol) Ph₃P in 500 mL anhydrous Et₂O, 8.11 mL (51.4 mmol) DEAD was added. After 1 hr a solution of 3.80 mL (53.4 mmol) AcSH and 2.30 g (19.8 mmol) diol **11** in 165 mL anhydrous Et₂O was added dropwise via addition funnel over 30 min. Upon complete addition the reaction was kept at 0 °C for 1 hr and then warmed naturally to room temperature. Stirred for 10 hr. The reaction was filtered and triturated with cold anhydrous Et₂O. The filtrate was concentrated. The oil was purified via flash-chromatography using 10:1 hexanes/EtOAc eluent to provide 3.49 g (76%) of **12** as a clear oil. R_f = 0.46 (4:1 hexanes/EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 5.37 (t, *J* = 4.8 Hz, 2 H), 2.82 (t, *J* = 6.8 Hz, 4 H), 2.26 (s, 6 H), 2.24 (m, 4 H); ¹³C NMR (125 MHz, CDCl₃) δ 195.1 (C), 128.8 (CH), 30.3 (CH₃), 28.5 (CH₂), 27.0 (CH₂); Ir (neat) (neat) 3038 (w), 1682 (s), 1355 (m), 1130 (s), 1100 (s) cm⁻¹; HRMS (EI) *m/z* 233.0672 [(M+), calcd. for C₁₀H₁₆O₂S₂: 233.0670].

4.2.4 Hex-3-ene-1,6-dithiol (8)—In an air-dried flask 0.872 g (6.31 mmol) K₂CO₃ was added to a stirring solution of 1.00 g (4.30 mmol) **12** in MeOH at room temperature. The reaction was filtered, concentrated, and taken up in 100 mL DCM:H₂O (1:1). After separation the DCM layer was washed once with 50 mL aqueous NH₄Cl_(aq) and two sequential times with 50 mL H₂O. The aqueous layers were combined and extracted two consecutive times with 50 mL DCM. The DCM extractions were combined, dried over MgSO₄, filtered and concentrated to afford 0.59 g (94%) of **8** as a foul-smelling oil. R_f = 0.11 (4:1 hexanes/EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 5.49 (t, *J* = 4.7 Hz, 2 H), 2.72 (t, *J* = 7.0 Hz, 4 H), 2.47 (q, *J* = 7.0 Hz, 4 H), 1.25 (br s, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 128.9 (CH), 38.4 (CH₂), 27.2 (CH₂); Ir (neat) 3010 (vw), 1690 (m), 1640 (s), 1415 (m), 1360 (m), 1235 (w), 1199 (s), 1100 (w) cm⁻¹; HRMS (EI) *m/z* 148.0382 [(M+), calcd. for C₆H₁₂S₂: 148.0380].

4.2.5 3,4,7,8-Tetrahydro-[1,2]dithiocine (2)—In an air-dried flask 0.853 g (4.02 mmol) CsF-celite was added to a stirring solution of 0.390 g (2.66 mmol) **8** in 89 mL ACN (30 mM) at room temperature. The reaction was vigorously stirred at room temperature for 5 d. After filtration the solid was triturated with ACN and the filtrate concentrated to provide an oil which was purified via alumina (basic; activity 1) chromatography using hexanes eluent to provide 0.249 g (65%) of **2** as a clear oil with a distinct disulfide odor. R_f = 0.87 (4:1 hexanes/EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 5.67 (m, 2 H), 2.87 (m, 2 H), 2.64 (m, 4 H), 2.50 (2 H); ¹³C NMR (125 MHz, CDCl₃) δ 129.7 (CH), 39.4 (CH₂), 27.2 (CH₂); Ir (neat)

3010 (w), 1645 (w), 1448 (m), 1407 (m), 1279 (m), 1249 (w), 966 (w), 886 (w), 726 (s) cm^{-1} ; HRMS (EI) m/z 146.0225 [(M+), calcd. for $\text{C}_6\text{H}_{10}\text{S}_2$: 146.0224].

4.3 Synthesis of dithiocine dimer 18

4.3.1 (E)-Hex-3-enedioic acid dimethyl ester (14)—In an air-dried flask 1 drop H_2SO_4 was added to a stirring solution of 2.01 g (13.9 mmol) *trans*-mucionic acid in 50 mL MeOH at room temperature. The reaction was heated to reflux (oil-bath=90 °C) and stirred for 16 hrs. Cooled to room temperature and partitioned with 40 mL DCM:H₂O (1:1). After separation the aqueous layer was extracted two consecutive times with 20 mL DCM. The DCM extractions were combined, dried over MgSO_4 , filtered and concentrated to afford 2.32 g (97%) of **14** as a sweet-smelling oil. $R_f = 0.41$ (2:1 hexanes/EtOAc); ^1H NMR (500 MHz, CDCl_3) δ 5.61 (m, 2 H), 3.59 (s, 6 H), 3.01 (d, $J = 1.5$ Hz, 4 H); ^{13}C NMR (125 MHz, CDCl_3) δ 171.5 (C), 125.7 (CH), 51.5 (CH_2), 37.3 (CH_3); Ir (neat) 1729 (s), 1453 (m), 1360 (w), 1251 (m), 1154 (s) cm^{-1} ; LRMS (EI) m/z 172.0 [(M+) calcd. for $\text{C}_8\text{H}_{12}\text{O}_4$: 172.0].⁵¹

4.3.2 (E)-Hex-3-ene-1,6-diol (15)—To a stirring solution of 0.919 g (24.2 mmol) LAH in 16 mL anhydrous THF previous cooled to 0 °C, a solution of 2.08 g (12.1 mmol) **14** in 4 mL anhydrous THF was added dropwise via syringe. Upon complete addition the reaction was stirred at 0 °C for 10 min then heated to reflux (oil-bath=40 °C) and stirred for 4 hrs. Cooled to room temperature and quenched cautiously with H₂O. After filtration the filtrate layers were separated. The aqueous layer was extracted two consecutive times with 50 mL Et₂O. The ethereal extractions were combined, dried over MgSO_4 , filtered and concentrated to afford 1.23 g (88%) of **15** as a clear oil. $R_f = 0.17$ (1:2 hexanes/EtOAc); ^1H NMR (500 MHz, CDCl_3) δ 5.49 (t, $J = 1.5$ Hz, 2 H), 3.59 (t, $J = 6.0$ Hz, 4 H), 3.57 (br s, 2 H), 2.24 (q, $J = 2.0$ Hz, 4 H); ^{13}C NMR (125 MHz, CDCl_3) δ 129.2 (CH), 61.4 (CH_2), 35.7 (CH_2); Ir (neat) 3386 (s), 3336 (s), 1741 (m), 1435 (m), 1365 (m), 1051 (s) cm^{-1} ; LRMS (EI) m/z 116.0 [(M+) calcd. for $\text{C}_6\text{H}_{12}\text{O}_2$: 116.0].⁵¹

4.3.3 Thioacetic acid S-(6-acetylsulfanyl-(E)-hex-3-enyl) ester (16)—Procedure and workup analogous to **12** using 2.32 g (19.9 mmol) **15**. After workup and concentration the oil obtained was purified via flash-chromatography using 10:1 hexanes/EtOAc eluent to provide 3.61 g (78%) of **16** as a clear oil. $R_f = 0.42$ (4:1 hexanes/EtOAc); ^1H NMR (500 MHz, CDCl_3) δ 5.44 (m, 2 H), 2.88 (t, $J = 7.3$ Hz, 4 H), 2.30 (s, 6 H), 2.23 (m, 4 H); ^{13}C NMR (125 MHz, CDCl_3) δ 195.6 (C), 129.7 (CH), 32.3 (CH_2), 30.5 (CH_3), 28.7 (CH_2); Ir (neat) 3015 (w), 1686 (s), 1429 (m), 1353 (ms), 1131 (s) cm^{-1} ; HRMS (EI) m/z 233.0662 [(M+H), calcd. for $\text{C}_{10}\text{H}_{16}\text{O}_2\text{S}_2$: 233.0670].

4.3.4 (E)-Hex-3-ene-1,6-dithiol (17)—Procedure and workup analogous to **8** using 0.718 g (3.09 mmol) **16** as substrate. After workup and concentration the oil obtained was purified without delay, to avoid oligomer formation, after impregnation onto flash silica gel via gradient flash-chromatography (hexanes to 10:1 to 4:1 to 1:1 to EtOAc) to provide 0.421 g (92%) of **17** as a clear foul-smelling oil. $R_f = 0.55$ (4:1 hexanes/EtOAc); ^1H NMR (500 MHz, CDCl_3) δ 5.47 (m, 2 H), 2.57 (q, $J = 7.7$ Hz, 4 H), 2.33 (m, 4H), 1.42 (t, $J = 7.7$ Hz, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 129.6 (CH), 38.7 (CH_2), 25.6 (CH_2); Ir (neat) 3015 (w), 1739 (ms), 1429 (s), 1278 (ms), 1227 (ms) cm^{-1} ; HRMS (EI) m/z 148.0379 [(M+) calcd. for $\text{C}_6\text{H}_{12}\text{S}_2$: 148.0380].

4.3.5 1,2,9,10-tetrathia-Cyclohexadeca-5,13-diene (18)—Procedure and workup analogous to **2** using 1.85 g (12.7 mmol) **17** in ACN (30.0 μM). After workup and concentration the oil obtained was purified via gradient alumina (basic; activity 1) chromatography (hexanes to 50:1 to 25:1 to 10:1 to 4:1 to EtOAc) to provide 0.192 g (21%) of **18** as a distinctly disulfide-smelling oil. $R_f = 0.65$ (4:1 hexanes/EtOAc); ^1H NMR (500

MHz, CDCl₃) δ 5.62 (m, 2 H), 2.79 (t, *J* = 7.1 Hz, 4 H), 2.40 (m, 4 H); ¹³C NMR (125 MHz, CDCl₃) δ 129.8 (CH), 39.7 (CH₂), 31.8 (CH₂); Ir (neat) 3010 (w), 1450 (m), 1410 (m), 1268 (m) cm⁻¹; HRMS (EI) *m/z* 292.0446 [(M+), calcd. for C₁₂H₂₀S₄: 292.0448].

4.4 Synthesis of dithiazacanone 4

4.4.1 3-Tritylsulfanyl-propionic acid (21)—In an air-dried flask 10.5 g (37.6 mmol) TrtCl was added to a stirring solution of 3.30 mL (37.6 mmol) **19** in 754 mL (0.05 M) DCM at room temperature. The reaction was stirred at room temperature for 14 hrs and then concentrated. The solid was purified upon recrystallization from MeOH/H₂O to provide 10.7 g (82%) **21** as a white solid.³⁹ *R*_f = 0.60 (4:1 hexanes/EtOAc); mp = 202–204 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 12.2 (br s, 1 H), 7.33 (s, 12 H), 7.24 (m, 3 H), 2.29 (t, *J* = 7.3 Hz, 2 H), 2.17 (t, *J* = 7.3 Hz, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 178.6 (C), 144.5 (C), 129.4 (CH), 127.7 (CH), 126.4 (CH), 66.6 (C), 33.3 (CH₂), 26.7 (CH₂); Ir (neat) 3463 (w), 3010 (s), 2748 (m), 2650 (m), 2569 (m), 1700 (vs), 1429 (s) cm⁻¹; 1231 (s); HRMS (EI) *m/z* 347.1110 [(M-H), calcd. for C₂₂H₂₀O₂S: 347.1106].^{29,35}

4.4.2 2-Tritylsulfanyl-ethylamine (22)—In an air-dried flask 4.90 g (17.6 mmol) TrtCl was added to a stirring solution of 2.00 g (17.6 mmol) **20** in TFA at room temperature where upon dissolution resulted in a deep red color. The reaction was set-aside for 1 hr and subsequently poured into 200 mL water. The solution was made basic by the addition of concentrated KOH_{aq} and vacuum-filtered. The solid was dried over CaSO₄ and high-vacuum. The mono/di-protected mixture was dissolved in 1:1 HCl/ACN and poured into ether (10:1 ether/HCl:ACN). The solution was filtered and the solid triturated with ether. Concentrated KOH_{aq} was added to the ethereal solution (1:1) and stirred vigorously mixed for 45 min. After partitioning the ethereal was dried over MgSO₄, filtered, and concentrated to afford a 5.62 g (100%) of **22** as a white solid. *R*_f = 0.17 (4:1 hexanes/EtOAc); mp = 146–148 °C; ¹H NMR (500 MHz, CDCl₃) 7.41 (m, 6 H), 7.27 (m, 6 H), 7.20 (m, 3 H), 2.68 (br s, 2 H), 2.52 (t, *J* = 6.4 Hz, 2 H), 2.36 (t, *J* = 6.4 Hz, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 144.6 (C), 129.5 (CH), 127.9 (CH), 126.7 (CH), 66.6 (C), 40.4 (CH₂), 34.7 (CH₂); Ir (neat) 3379 (br m), 3057 (w), 2932 (w), 1680 (m), 1484 (m), 1439 (m), 1206 (m), 1130 (m), 698 (s) cm⁻¹; HRMS (EI) *m/z* 320.1489 [(M+H), calcd. for C₂₁H₂₁NS: 320.1473].^{29,35}

4.4.3 3-Tritylsulfanyl-N-(2-tritylsulfanyl-ethyl)-propionamide (23)—To a stirring solution of 1.39 g (3.99 mmol) acid **21** and 1.26 g (3.95 mmol) amine **22** in 40 mL DCM was added 0.69 mL (5.01 mmol) Et₃N followed by 1.06 g (7.84 mmol) HOBt. For complete dissolution 2 mL DMF was added. The reaction was stirred at room temperature for 18 hrs and then vacuum-filtered. The filtrate was partitioned with the addition of 50 mL 10% aq, NaHCO₃. After separation the DCM layer was washed once with 50 mL 10% aq, NaHCO₃. The DCM layer was dried over MgSO₄, filtered and concentrated. After impregnation onto flash silica the acid was purified via gradient flash-chromatography (hexanes to 10:1 to 4:1 to 1:1 to EtOAc) to afford 1.72 g (67%) **23** as a white solid. *R*_f = 0.07 (4:1 hexanes/EtOAc); mp = 138–141 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.39 (m, 12 H), 7.25 (m, 12 H), 7.19 (m, 6 H), 5.29 (t, *J* = 6.0 Hz, 1 H), 2.99 (q, *J* = 6.2 Hz, 2 H), 2.44 (t, *J* = 7.3 Hz, 2 H), 2.34 (t, *J* = 6.2 Hz, 2 H), 1.92 (t, *J* = 7.5 Hz, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 170.5 (C), 144.6 (C), 144.5 (C), 129.5 (CH), 129.4 (CH), 127.9 (CH), 127.8 (CH), 129.7 (CH), 126.6 (CH), 66.8 (C), 66.7 (C), 38.0 (CH₂), 35.5 (CH₂), 31.8 (CH₂), 27.6 (CH₂); Ir (neat) 3469 (m), 3058 (m), 2933 (m), 1703 (s), 1488 (s), 1444 (s), 1252 (m), 1155 (m), 1074 (m), 1009 (m), 695 (s) cm⁻¹; HRMS (EI) *m/z* 688.2094 [(M+K), calcd. for C₄₃H₃₉NOS₂: 688.2110].²⁹

4.4.4 3-Mercapto-N-(2-mercapto-ethyl)-propionamide (25)—In an air-dried flask 256 mL TFA was added to a stirring solution of 5.00 g (7.69 mmol) **23** in 512 mL (15 mM) DCM at room temperature. The yellow color produced was then quenched by the addition of

4.96 mL (30.7 mmol) TES. Upon complete addition the reaction was stirred at room temperature for 1 hr and then concentrated. The oil was redissolved in 500 mL DCM and concentrated. This was repeated two additional times. After impregnation onto flash silica the dithiol was purified via flash-chromatography (4:1 hexanes/EtOAc) to provide 1.16 g (92%) **25** as a foul-smelling oil. $R_f = 0.72$ (1:1 hexanes/EtOAc); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 5.98 (br s, 1 H), 3.46 (q, $J = 6.3$ Hz, 2 H), 2.82 (q, $J = 8.7$ Hz, 2 H), 2.68 (q, $J = 8.7$ Hz, 2 H), 2.52 (t, $J = 6.3$ Hz, 2 H), 1.63 (t, $J = 8.7$ Hz, 1 H), 1.39 (t, $J = 8.7$ Hz, 1 H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 170.7 (C), 42.3 (CH_2), 40.3 (CH_2), 24.6 (CH_2), 20.4 (CH_2); Ir (neat) 3283 (m), 3076 (w), 2933 (w), 1640 (s), 1539 (s), 1420 (m), 1355 (m), 258 (m), 1198 (m) cm^{-1} ; HRMS (EI) m/z 243.4738 [(M+2K), calcd. for $\text{C}_5\text{H}_{11}\text{NOS}_2$: 243.4735].

4.4.5 [1,2,5]-Dithiazocan-6-one (4)—Procedure and workup analogous to **2** using 0.39 g (2.35 mmol) **25** as substrate in ACN (1 mM). After workup the oil was triturated with hexanes overnight. The white solid obtained after filtration with triturated with excess DCM to provide 70.2 mg (18%) **4** in two conformations (1.7:1.0) as a white solid. $R_f = 0.65$ (1:1 hexanes/EtOAc); mp = 178–181 °C; $^1\text{H NMR}$ (500 MHz, $\text{DMSO}-d_6$) δ *Major conformer*: 8.15 (m, 1 H), 3.32 (m, 2 H), 2.90 (m, 2 H), 2.79 (m, 2 H), 2.47 (m, 2 H); *Minor conformer*: 8.22 (m, 1 H), 3.31 (m, 2 H), 2.89 (m, 2 H), 2.84 (m, 2 H), 2.52 (m, 2 H); $^{13}\text{C NMR}$ (125 MHz, $\text{DMSO}-d_6$) δ *Major conformer*: 170.1 (C), 37.6 (CH_2), 37.0 (CH_2), 34.4 (CH_2), 33.9 (CH_2); *Minor conformer*: 173.3 (C), 39.0 (CH_2), 38.9 (CH_2), 37.5 (CH_2), 34.9 (CH_2); Ir (neat) 3287 (m), 3068 (w), 2925 (w), 1633 (s), 1542 (s), 1416 (m), 1358 (m), 1258 (m), 1201 (m), 710 (w) cm^{-1} ; HRMS (EI) m/z 163.0120 [(M+), calcd. for $\text{C}_5\text{H}_9\text{NOS}_2$: 163.0126].²⁹

4.5 Synthesis of *N*-Me dithiazacanone 5

4.5.1 *N*-Methyl-3-tritylsulfanyl-*N*-(2-tritylsulfanyl-ethyl)-propionamide (24)—A solution of 1.55 g (2.38 mmol) **23** in 5 mL anhydrous DMF was added dropwise to a solution of 0.22 g (5.72 mmol) NaH in 20 mL anhydrous DMF previously chilled to 0 °C. After complete addition the reaction was stirred at 0 °C for 10 min, after which 1.18 mL (19.0 mmol) MeI was added rapidly dropwise. The reaction was stirred at 0 °C for 30 min and then warmed naturally to room temperature. The reaction was stirred at room temperature for 14 hrs and then quenched with excess phosphate buffer (pH=7). The solution was then poured into 100 mL EtOAc and the biphasic solution separated. The EtOAc layer was washed once with 100 mL brine, dried over MgSO_4 , filtered and concentrated. After impregnation onto flash silica the *N*-methyl amide was purified via gradient flash-chromatography (hexanes to 10:1 to 4:1 to 1:1 to EtOAc to DCM) to provide 1.37 g (87%) **24** in two indistinguishable conformations (~1.0:1.0) as a white solid. $R_f = 0.45$ (4:1 hexanes/EtOAc); mp = 146–148; $^1\text{H NMR}$ (500 MHz, CDCl_3) δ *Conformer mixture*: 7.45 (dd, $J = 16.1, 7.3$ Hz, 24 H), 7.28 (m, 24 H), 7.22 (m, 12 H), 3.06 (t, $J = 7.3$ Hz, 2 H), 2.80 (t, $J = 7.3$ Hz, 2 H), 2.56 (s, 3 H), 2.49 (m, 4 H), 2.47 (s, 3 H), 2.34 (t, $J = 7.3$ Hz, 2 H), 2.29 (t, $J = 7.3$ Hz, 2 H), 2.02 (t, $J = 7.3$ Hz, 2 H), 1.93 (t, $J = 7.3$ Hz, 2 H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ *Conformer mixture*: 170.6 (C), 170.5 (C), 144.8 (C), 144.7 (C), 144.6 (C), 144.4 (C), 129.6 (CH), 129.5 (CH), 129.5 (CH), 129.4 (CH), 127.9 (CH), 127.8 (CH), 127.7 (CH), 127.7 (CH), 126.8 (CH), 126.6 (CH), 126.5 (CH), 126.5 (CH), 67.2 (C), 66.7 (C), 66.7 (C), 66.6 (C), 48.8 (CH_2), 47.2 (CH_2), 35.6 (CH_3), 33.1 (CH_3), 32.7 (CH_2), 32.1 (CH_2), 29.8 (CH_2), 29.5 (CH_2), 27.2 (CH_2), 27.0 (CH_2); Ir (neat) 3464 (m), 3062 (m), 2924 (m), 1694 (m), 1489 (m), 1444 (s), 1148 (s), 1009 (s), 755 (s), 695 (s) cm^{-1} ; HRMS (EI) m/z 664.2714 [(M+K), calcd. for $\text{C}_{44}\text{H}_{41}\text{NOS}_2$: 664.2708].

4.5.2 3-Mercapto-*N*-(2-mercapto-ethyl)-*N*-methyl-propionamide (26)—Procedure and workup analogous to **25** using 1.37 g (2.06 mmol) **24** as substrate. After impregnation

onto flash silica the disulfide was purified via gradient flash-chromatography (hexanes to 10:1 to 4:1 to EtOAc to DCM) to provide 0.33 g (92%) **25** in two indistinguishable conformations (~1.0:1.0) as a foul-smelling oil. $R_f = 0.32$ (1:2 hexanes/EtOAc); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ *Conformer mixture*: 3.65 (br m, 2 H), 3.56 (br m, 1 H), 3.36 (br m, 1 H), 3.07 (br m, 4 H), 2.95 (br s, 6 H), 2.86 (br m, 4 H), 2.76 (br m, 3 H), 2.62 (br m, 1 H), 1.72 (br m, 2 H), 1.62 (br m, 2 H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ *Conformer mixture*: 176.0 (C), 175.6 (C), 49.8 (CH_2), 49.5 (CH_2), 33.5 (CH_3), 33.4 (CH_3), 29.7 (CH_2), 29.6 (CH_2), 25.4 (CH_2), 25.3 (CH_2), 24.7 (CH_2), 24.7 (CH_2); Ir (neat) 3301 (w), 2927 (m), 1671 (s), 1628 (s), 1548 (m), 1414 (m), 1135 (s), 1046 (m), 704 (m) cm^{-1} ; HRMS (EI) m/z 179.0437 [(M+), calcd. for $\text{C}_6\text{H}_{13}\text{NOS}_2$: 179.0439].

4.5.3 5-Methyl-[1,2,5]dithiazocan-6-one (5)—Procedure and workup analogous to **2** using 96.1 mg (0.53 mmol) **26** in ACN (1 mM). After impregnation onto flash silica the disulfide was purified via gradient flash-chromatography (hexanes to 10:1 to 4:1 to 2:1 to EtOAc to DCM to 10% MeOH/DCM) to provide 33.8 mg (36%) **5** in indistinguishable interconverting conformations as a water-white oil. $R_f = 0.09$ (4:1 hexanes/EtOAc); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ *Conformer mixture*: 4.25 (m, 2 H), 3.51 (m, 2 H), 3.16 (m, 2 H), 2.93 (m, 8 H), 2.88 (m, 6 H), 2.76 (m, 2 H); $^{13}\text{C NMR}$ at -18°C (125 MHz, CDCl_3) δ *Major*: 174.2 (C), 54.3 (CH_2), 37.8 (CH_2), 36.8 (CH_2), 34.1 (CH_3), 30.7 (CH_2); *Minor*: 176.4 (C), 47.2 (CH_2), 37.9 (CH_2), 37.3 (CH_2), 36.6 (CH_2), 32.2 (CH_3); Ir (neat) 3464 (m), 2921 (m), 1632 (s), 1462 (m), 1397 (m), 1284 (w), 1172 (w) cm^{-1} ; LRMS (EI) m/z 2921 (m), 1632 (s), 1462 (m), 1397 (m), 1284 (w), 1172 (w); HRMS (EI) m/z 177.0283 [(M+), calcd. for $\text{C}_6\text{H}_{11}\text{NOS}_2$: 177.0282].

4.6 Synthesis of dipeptide 6

4.6.1 2R-(2R-Acetylamino-3-tritylsulfanyl-propionylamino)-3-tritylsulfanyl-propionamide (29)—Peptide coupling of 0.50 g (1.23 mmol) **27** and 0.45 g (1.25 mmol) **28** was analogous to the production of compound **23** in DCM:DMF (0.1 M DCM). After impregnation onto flash silica the protected dipeptide was purified via gradient flash-chromatography (10:1 hexanes/EtOAc to 4:1 to 1:1 to EtOAc to DCM to 2.5% MeOH/DCM to 10% MeOH/DCM) to provide 0.72 g (79%) **29** as a white-solid. $R_f = 0.56$ (5% MeOH/DCM); $[\alpha]_D^{20} = -22.2$ (c 0.09, CHCl_3); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.47 (m, 12 H), 7.32 (m, 12 H), 7.26 (m, 6 H), 6.45 (d, $J = 7.8$ Hz, 2 H), 6.16 (d, $J = 6.8$ Hz, 1 H), 5.67 (s, 1 H), 4.21 (dd, $J = 12.6, 6.8$ Hz, 1 H), 4.09 (dd, $J = 13.1, 6.3$ Hz, 1 H), 2.90 (dd, $J = 12.6, 6.3$ Hz, 1 H), 2.73 (dd, $J = 13.1, 6.3$ Hz, 1 H), 2.66 (dd, $J = 13.1, 6.3$ Hz, 1 H), 2.56 (dd, $J = 13.1, 5.3$ Hz, 1 H), 1.92 (s, 3 H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 171.6 (C), 170.3 (C), 169.7 (C), 144.2 (CH), 144.0 (CH), 129.4 (CH), 129.2 (CH), 128.0 (CH), 127.9 (CH), 129.9 (C), 126.8 (C), 67.1 (C), 67.0 (C), 52.2 (CH), 51.8 (CH), 33.2 (CH_2), 32.9 (CH_2), 22.8 (CH_3); Ir (neat) 3255 (m), 3056 (m), 2930 (w), 1744 (w), 1650 (s), 1488 (s), 1442 (s), 1032 (w), 697 (s) cm^{-1} ; HRMS (EI) m/z 772.2637 [(M+K), calcd. for $\text{C}_{46}\text{H}_{43}\text{N}_3\text{O}_3\text{S}_2$: 772.2644].

4.6.2 2R-(2R-Acetylamino-3-mercapto-propionylamino)-3-mercapto-propionamide (30)—Procedure and workup analogous to **25** using 0.20 g (0.26 mmol) **29** as substrate in DCM (2 mM). After impregnation onto flash silica the dithiol was purified via gradient flash-chromatography (hexanes to DCM to EtOAc) to provide 64.5 mg (91%) of **30** as a foul-smelling oil. $R_f = 0.1$ (10% MeOH/DCM); $[\alpha]_D^{20} = -13.6$ (c 0.22, CHCl_3); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 6.99 (br m, 2 H), 6.39 (br m, 1 H), 5.59 (br m, 1 H), 4.60 (dd, $J = 9.6, 6.4$ Hz, 1 H), 4.51 (dd, $J = 13.3, 6.2$ Hz, 1 H), 3.08 (dd, $J = 7.9$ Hz, 6.2 Hz, 1 H), 3.00 (dd, $J = 13.3, 6.6$ Hz, 1 H), 2.90 (dd, $J = 12.4, 7.3$ Hz, 1 H), 2.81 (dd, $J = 13.1, 6.6$ Hz, 1 H), 2.08 (s, 3 H), 1.70 (m, 1 H), 1.60 (m, 1 H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 178.2 (C), 175.4 (C), 173.9 (C), 67.1 (CH), 65.0 (CH), 32.3 (CH_2), 31.9 (CH_2), 23.7 (CH_3); Ir (neat) 3282

(m), 3021 (m), 1741 (m), 1633 (s), 1535 (s), 1444 (s), 1211 (m), 1171 (s), 699 (s) cm^{-1} ;
HRMS (EI) m/z 304.0186 [(M+K), calcd. for $\text{C}_8\text{H}_{15}\text{N}_3\text{O}_3\text{S}_2$: 304.0192].

4.6.3 7*R*-Acetylamino-6-oxo-[1,2,5]dithiazocane-4*R*-carboxylic acid amide (**6**)—

Procedure and workup analogous to **2** using 70.9 mg (0.26 mmol) **30** as substrate in ACN (1 mM). After impregnation onto flash silica the disulfide was purified via gradient flash-chromatography (DCM to 2.5% MeOH/DCM to 5% MeOH/DCM to 10% MeOH/DCM).

$R_f=0.27$ (10% MeOH/DCM); $[\alpha]_D^{20} = -24.4$ (c 0.08, D_2O); ^1H NMR (500 MHz, $\text{DMSO}-d_6/\text{D}_2\text{O}$) δ *T*-conformer: 8.09 (s, 1 H), 7.73 (s, 1 H), 7.39 (s, 1 H), 7.28 (s, 1 H), 4.96 (m, 1 H), 4.29 (m, 1 H), 3.68 (m, 1 H), 3.42 (m, 1 H), 3.39 (m, 1 H), 3.28 (m, 1 H), 2.11 (s, 3 H); *T'*-conformer: 8.62 (d, $J = 5.0$ Hz, 1 H), 8.03 (d, $J = 5.1$ Hz, 1 H), 7.53 (m, 1 H), 7.09 (s, 1 H), 4.95 (m, 1 H), 3.98 (m, 1 H), 3.63 (m, 1 H), 3.59 (m, 1 H), 3.44 (m, 1 H), 3.43 (m, 1 H), 2.07 (s, 3 H); *C*-conformer: 8.54 (m, 1 H), 8.22 (d, $J = 7.2$ Hz, 1 H), 8.15 (d, $J = 7.2$ Hz, 1 H), 6.92 (m, 1 H), 5.10 (m, 1 H), 4.98 (m, 1 H), 3.53 (m, 1 H), 3.05 (m, 1 H), 3.02 (m, 1 H), 2.74 (m, 1 H), 2.05 (s, 3 H); *C+* conformer: 8.29 (s, 1 H), 7.58 (s, 1 H), 7.42 (s, 1 H), 7.37 (s, 1 H), 5.23 (m, 1 H), 5.11 (m, 1 H), 3.41 (m, 1 H), 3.20 (m, 1 H), 3.15 (m, 1 H), 2.74 (m, 1 H), 2.02 (s, 3 H); ^{13}C NMR (125 MHz, CDCl_3) δ *T*-conformer: 180.3 (C), 176.4 (C), 175.3 (C), 59.1 (CH), 56.7 (CH), 49.8 (CH_2), 48.6 (CH_2), 24.4 (CH_3); *T'*-conformer: 176.1 (C), 175.6 (C), 174.9 (C), 57.4 (CH), 54.4 (CH), 50.9 (CH_2), 43.3 (CH_2), 24.4 (CH_3); *C*-conformer: 176.5 (C), 174.0 (C), 173.8 (C), 55.6 (CH), 55.2 (CH), 45.0 (CH_2), 43.3 (CH_2), 24.4 (CH_3); *C+* conformer: 176.1 (C), 174.7 (C), 173.6 (C), 61.7 (CH), 52.2 (CH), 44.5 (CH_2), 41.2 (CH_2), 24.3 (CH_3); Ir (neat) 3265 (br s), 1642 (s), 1516 (m), 1403 (m), 1179 (w) cm^{-1} ; HRMS (EI) m/z 264.0466 [(M+), calcd. for $\text{C}_8\text{H}_{13}\text{N}_3\text{O}_3\text{S}_2$: 264.0476].⁵

4.7 Synthesis of *N*-Me dipeptide 7

4.7.1 4*R*-*tert*-Butyldisulfanylmethyl-5-oxo-oxazolidine-3-carboxylic acid 9*H*-fluoren-9-ylmethyl ester (**32**)—

To a room temperature solution of 10.0 g (23.1 mmol) Fmoc-Cys(StBu)-OH in 230 mL PhH under natural atmosphere was added 3.59 g (155.1 μg ; 1 mmol) *p*-formaldehyde and 0.37 g (7 mol%) camphorsulfonic acid. The reaction was heated to reflux (oil-bath=100 °C) in a Dean-Stark apparatus and stirred for 14 h. The reaction was concentrated to provide a clear oil. After impregnation onto flash silica the oxazolidinone was purified via gradient flash-chromatography (hexanes to 10:1 to 4:1 to 1:1 to EtOAc) to provide 9.63 g (94%) **32** as a white viscous gum. $R_f = 0.71$ (EtOAc); $[\alpha]_D^{20} = -13.6$ (c 0.23, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.76 (d, $J = 7.6$ Hz, 2 H), 7.55 (d, $J = 7.6$ Hz, 2 H), 7.40 (t, $J = 7.6$ Hz, 2 H), 7.31 (m, 2 H), 5.5–5.2 (br m's, 2 H), 4.75–4.35 (br m's, 2 H), 4.24 (br s, 1 H), 4.01 (br s, 1 H), 3.53 (br s, 0.5 H), 3.20 (br s, 0.5 H), 2.97 (br s, 0.5 H), 2.66 (br s, 0.5 H), 1.26 (s, 9 H); ^{13}C NMR (125 MHz, CDCl_3) δ 170.8 (C), 152.2 (C), 143.4 (C), 141.4 (C), 127.9 (CH), 127.2 (CH), 124.6 (CH), 120.0 (CH), 78.4 (CH_2), 73.9 (CH_2), 67.6 (CH), 55.3 (C), 48.2 (CH), 47.2 (CH_2), 29.6 (CH_3); IR (neat) 1800 (s), 1714 (s), 1417 (s), 1288 (m), 1129 (m), 1052 (m), 910 (w), 737 (m) cm^{-1} ; HRMS (EI) m/z 444.1308 [(M+), calcd. for $\text{C}_{23}\text{H}_{25}\text{NO}_4\text{S}_2$: 444.1303].³⁹

4.7.2 3-*tert*-Butyldisulfanyl-2*R*-[(9*H*-fluoren-9-ylmethoxycarbonyl)-methyl-amino]-propionic acid (**33**)—

To a room temperature stirring solution of 9.03 g (20.3 mmol) **32** in 101 mL CHCl_3 under natural atmosphere was added 32.8 mL (203 mmol) TES followed by the rapid addition of 50 mL TFA. The reaction was stirred at room temperature for 16 h and then concentrated. The oil was dissolved in 150 mL DCM and concentrated. This was repeated three consecutive times. After impregnation onto flash silica, MeCys **33** was purified via gradient flash-chromatography (hexanes to 10:1 to 4:1 to 2:1; 1:1 to EtOAc) to provide 8.05 g (89%) **33** as a white solid in a 1.5:1.0 conformer ratio. $R_f=0.32$ (EtOAc); $[\alpha]_D^{20} = -30.4$ (c 0.33, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ Major conformer:

10.36 (br s, 1 H), 7.82 (m, 2 H), 7.69 (m, 2 H), 7.46 (m, 2 H), 7.39 (m, 2 H), 4.91 (dd, $J = 10.5, 4.3$ Hz, 1 H), 4.52 (m, 2 H), 4.36 (t, $J = 7.1$ Hz, 1 H), 3.47 (dd, $J = 13.9, 4.3$ Hz, 1 H), 3.25 (dd, $J = 13.9, 10.7$ Hz, 1 H), 3.13 (s, 3 H), 1.43 (s, 9 H); *Minor conformer*: 10.36 (br s, 1 H), 7.81 (m, 2 H), 7.68 (m, 2 H), 7.46 (m, 2 H), 7.39 (m, 2 H), 4.86 (m, 1 H), 4.63 (dd, $J = 10.5, 6.4$ Hz, 1 H), 4.57 (m, 1 H), 4.32 (t, $J = 6.0$ Hz, 1 H), 3.33 (dd, $J = 12.2, 5.5$ Hz, 0.5 H), 3.23 (dd, $J = 13.9, 4.7$ Hz, 1 H), 3.06 (s, 3 H), 2.84 (dd, $J = 13.7, 10.5$ Hz, 0.5 H), 1.41 (s, 9 H); ^{13}C NMR (125 MHz, CDCl_3) δ *Major conformer*: 174.4 (C), 156.5 (C), 143.5 (C), 141.0 (C), 127.4 (CH), 126.8 (CH), 124.8 (CH), 124.6 (CH), 67.9 (CH_2), 59.5 (CH), 48.0 (C), 46.8 (CH), 38.8 (CH_2), 33.4 (CH_3), 29.7 (CH_3); *Minor conformer*: 174.3 (C), 156.1 (C), 143.6 (C), 141.0 (C), 127.2 (CH), 126.9 (CH), 124.9 (CH), 124.7 (CH), 67.8 (CH_2), 58.5 (CH), 47.9 (C), 46.7 (CH), 39.0 (CH_2), 32.7 (CH_3), 29.7 (CH_3); IR (neat) 3353 (w), 1702 (s), 1449 (s), 1399 (m), 1317 (s), 1165 (s), 1129 (m), 976 (w), 738 (s) cm^{-1} ; HRMS (EI) m/z 446.1457 [(M+), calcd. for $\text{C}_{23}\text{H}_{27}\text{NO}_4\text{S}_2$: 446.1460].³⁹

4.7.3 3-*tert*-Butyldisulfanyl-2*R*-[(9*H*-fluoren-9-ylmethoxycarbonyl)-methyl-amino]-propionic acid methyl ester (**34**)

In an air-dried flask 0.08 g (0.59 mmol) K_2CO_3 was added to a stirring solution of 0.26 g (0.54 mmol) **33** in 0.5 mL DMF previously chilled to 0 °C. Upon complete addition 0.06 mL (1.08 mmol) MeI was added and the reaction was stirred at 0 °C for 30 min. The ice-bath was removed and the reaction was stirred for 1 hr. The reaction was then filtered and concentrated. After impregnation onto flash silica the *N*-Me amino ester was purified via gradient flash-chromatography (hexanes to 10:1 to 4:1 to 1:1 to EtOAc to DCM) to provide (95%) **34** as a water-white oil in a 2.0:1.0 conformer ratio. $R_f=0.86$ (EtOAc); $[\alpha]_D^{20} = -268.5$ (c 0.35, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ *Major conformer*: 7.76 (d, $J = 7.5$ Hz, 2 H), 7.60 (d, $J = 7.5$ Hz, 2 H), 7.40 (t, $J = 7.5$ Hz, 2 H), 7.31 (dt, $J = 7.5, 7.3$ Hz, 2 H), 4.79 (dd, $J = 10.3, 4.5$ Hz, 1 H), 4.41 (dd, $J = 13.9, 7.0$ Hz, 2 H), 4.30 (t, $J = 7.0$ Hz, 1 H), 3.74 (s, 3 H), 3.33 (dd, $J = 13.9, 4.7$ Hz, 1 H), 3.11 (dd, $J = 13.9, 10.5$ Hz, 1 H), 3.01 (s, 3 H), 1.34 (s, 9 H); *Minor conformer*: 7.76 (d, $J = 7.5$ Hz, 2 H), 7.58 (d, $J = 7.3$ Hz, 2 H), 7.40 (t, $J = 7.5$ Hz, 2 H), 7.31 (dt, $J = 7.5, 7.3$ Hz, 2 H), 4.72 (dd, $J = 9.0, 4.5$ Hz, 1 H), 4.52 (dd, $J = 10.1, 5.5$ Hz, 1 H), 4.46 (dd, $J = 9.6, 5.5$ Hz, 1 H), 4.25 (t, $J = 5.5$ Hz, 1 H), 3.61 (s, 3 H), 3.11 (dd, $J = 13.9, 10.5$ Hz, 1 H), 2.93 (s, 3 H), 2.73 (dd, $J = 13.9, 9.8$ Hz, 1 H), 1.32 (s, 9 H); ^{13}C NMR (125 MHz, CDCl_3) δ *Major conformer*: 169.5 (C), 150.5 (C), 143.8 (C), 141.3 (C), 127.6 (CH), 127.0 (CH), 125.1 (CH), 124.8 (CH), 73.1 (CH_2), 59.6 (CH), 48.1 (CH_3), 47.1 (CH_2), 42.7 (C), 39.6 (CH_2), 33.2 (CH_3), 29.9 (CH_3); *Minor conformer*: 170.6 (C), 153.2 (C), 144.5 (C), 139.9 (C), 127.4 (CH), 126.8 (CH), 125.0 (CH), 124.8 (CH), 67.8 (CH_2), 62.0 (CH), 52.5 (CH_3), 46.5 (CH_2), 42.8 (C), 39.4 (CH_2), 33.1 (CH_3), 29.8 (CH_3); IR (neat) 3010 (w), 1743 (s), 1700 (s), 1449 (m), 1312 (m), 1164 (s), 1000 (m), 737 (s) cm^{-1} ; HRMS (EI) m/z 459.1539 [(M+), calcd. for $\text{C}_{24}\text{H}_{29}\text{NO}_4\text{S}_2$: 459.1538].

4.7.4 2*R*-[(2*R*-Acetylamino-3-tritylsulfanyl-propionyl)-methyl-amino]-3-*tert*-butyldisulfanyl-propionic acid methyl ester (**35**)

To a room temperature solution of 0.89 g (1.95 mmol) **34** in 19.5 mL DCM was added 2.04 mL (19.5 mmol) Et_2NH . Stirred for 1.5 h and then concentrated. After dissolution in 21 mL DMF, 0.86 g (2.14 mmol) **27** and 0.81 g (2.14 mmol) HATU was added. Upon complete dissolution 0.48 mL (2.92 mmol) Hünigs base was added and the reaction was stirred at room temperature for 3 h. Reaction was poured into 100 mL EtOAc. The EtOAc layer was washed two consecutive times with 100 mL 10% aqueous NaHCO_3 , once with 100 mL H_2O , and once with 100 mL brine. The EtOAc layer was dried over MgSO_4 , filtered and concentrated. After impregnation onto flash silica the dipeptide was purified via gradient flash-chromatography (hexanes to 10:1 to 5:1 to 2:1 to 1:1 to EtOAc to 10% MeOH/DCM) to provide (68%) **35** as a white solid in a 1.0:1.0 conformer ratio. $R_f=0.45$ (EtOAc); $[\alpha]_D^{20} = -131.6$ (c 0.06, CHCl_3); ^1H NMR (500

MHz, CDCl₃) δ *Conformer mixture*: 7.39 (m, 12 H), 7.25 (m, 12 H), 7.18 (m, 6 H), 6.46 (br t, $J = 7.8$ Hz, 2 H), 4.93-4.82 (series of m's, 3 H), 4.64 (dd, $J = 9.7, 4.8$ Hz, 1 H), 3.61 (s, 3 H), 3.60 (s, 3 H), 3.29 (t, $J = 4.3$ Hz, 1 H), 3.26 (t, $J = 4.3$ Hz, 1 H), 3.05 (dd, $J = 13.6, 10.2$ Hz, 1 H), 2.93 (dd, $J = 14.1, 10.2$ Hz, 1 H), 2.87 (s, 3 H), 2.79 (s, 3 H), 2.51 (m, 4 H), 1.91 (s, 3 H), 1.90 (s, 3H), 1.29 (s, 9 H), 1.28 (s, 9 H); ¹³C NMR (125 MHz, CDCl₃) δ *Conformer mixture*: 175.1 (C), 174.6 (C), 171.2 (C), 170.9 (C), 169.8 (C), 169.7 (C), 144.4 (C), 144.4 (C), 129.5 (CH), 129.5 (CH), 127.9 (CH), 127.8 (CH), 126.7 (CH), 126.7 (CH), 66.9 (CH), 66.9 (CH), 61.0 (C), 59.4 (C), 58.0 (CH), 57.8 (CH), 52.4 (CH₃), 52.4 (CH₃), 48.4 (C), 48.1 (C), 38.7 (CH₂), 38.4 (CH₂), 34.4 (CH₂), 34.3 (CH₂), 29.9 (CH₃), 29.8 (CH₃), 29.7 (CH₃), 29.7 (CH₃), 23.1 (CH₃), 23.1 (CH₃); Ir (neat) 3327 (m), 2926 (s), 1734 (m), 1623 (m), 1567 (m), 1242 (m) cm⁻¹; HRMS (EI) m/z 624.2140 [(M+H), calcd. for C₃₃H₄₀N₂O₄S₃: 624.2150].

4.7.5 2R-[(2R-Acetylamino-3-tritylsulfanyl-propionyl)-methyl-amino]-3-mercapto-propionic acid methyl ester (36)—To a room temperature solution of 32.8 mg (52.4 μ mol) **35** in 0.5 mL DMF was added 80.9 g (0.52 mmol) dithiothreitol and 5 μ L (52.4 mol) *N*-methyl morpholine. Stirred for 24 h and then concentrated. Reaction was transferred into 50 mL EtOAc and the EtOAc layer was washed two consecutive times with 50 mL H₂O and once with 50 mL brine. The EtOAc layer was dried over MgSO₄, filtered and concentrated. The solid was purified via reverse-phase HPLC to provide 23.6 mg (84%)

36 as a white solid in a 1.0:1.0 conformer ratio. R_f=0.38 (EtOAc); [α]_D²⁰ = - 64.0 (*c* 0.07, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ *Conformer mixture*: 7.37 (m, 12 H), 7.29 (m, 12 H), 7.22 (m, 6 H), 6.59 (m, 2 H), 4.86 (m, 3 H), 4.64 (m, 1 H), 3.67 (s, 3 H), 3.66 (s, 3 H), 3.07 (m, 2 H), 2.91 (s, 3 H), 2.83 (s, 3 H), 2.75 (m, 1 H), 2.70 (m, 1 H), 2.56 (m, 2 H), 2.54 (m, 2 H), 2.03 (s, 3 H), 2.00 (s, 3 H), 1.59 (t, $J = 8.3$ Hz, 1 H), 1.51 (t, $J = 8.7$ Hz, 1 H); ¹³C NMR (125 MHz, CDCl₃) δ *Conformer mixture*: 173.3 (C), 172.3 (C), 171.4 (C), 170.7 (C), 170.2 (C), 169.7 (C), 144.5 (C), 144.4 (C), 129.5 (CH), 129.5 (CH), 127.9 (CH), 127.9 (CH), 126.8 (CH), 126.7 (CH), 67.1 (CH), 67.0 (CH), 59.4 (C), 58.9 (C), 54.0 (CH), 53.2 (CH), 52.6 (CH₃), 52.5 (CH₃), 34.4 (CH₂), 34.1 (CH₂), 33.8 (CH₂), 31.7 (CH₂), 30.0 (CH₃), 29.6 (CH₃), 23.1 (CH₃), 23.0 (CH₃); Ir (neat) 3288 (w), 3058 (w), 1740 (s), 1637 (s), 1487 (s), 1443 (s), 1241 (s), 1154 (s), 1097 (m), 1033 (m), 742 (s), 699 (s) cm⁻¹; HRMS (EI) m/z 575.1443 [(M+K), calcd. for C₂₉H₃₂N₂O₄S₂: 575.1441].

4.7.6 7R-Acetylamino-5-methyl-6-oxo-[1,2,5]dithiazocane-4R-carboxylic acid methyl ester (7)—In an air-dried flask 21.0 mg (67.9 μ mol) 2,2'-Dithiobis(5-nitropyridine) was added to a stirring solution of 36.1 mg (67.2 μ mol) **36** in 25 mL DCM at room temperature producing a yellow color over time. After 14 h, 10 mL TFA was added and the reaction an even brighter yellow color being produced over time. After 2 h the reaction was scavenged by the addition of 0.05 mL (0.33 mmol) TES creating a water-white reaction. Upon complete addition the reaction was stirred at room temperature for 8 h, once again with slow evolution of yellow color, and concentrated. The yellow solid was purified via reverse-phase HPLC to provide 7.0 mg (36%) **7** as a white solid in a single conformation and 12.5 mg (31%) **37** as a white solid in a single conformation. R_f=0.14 (EtOAc);

[α]_D²⁰ = - 19.2 (*c* 0.02, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 6.85 (s, 1 H), 5.31 (dd, $J = 11.9, 3.6$ Hz, 1 H), 5.13 (t, $J = 7.6$ Hz, 1 H), 3.81 (s, 3 H), 3.38 (dd, $J = 13.7, 3.9$ Hz, 1 H), 3.04 (d, $J = 14.0$ Hz, 1 H), 2.96 (d, $J = 13.7$ Hz, 1 H), 2.89 (dd, $J = 11.3, 2.4$ Hz, 1 H), 2.86 (s, 3 H), 2.01 (s, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 171.7 (C), 169.3 (C), 169.0 (C), 57.5 (CH), 52.1 (CH), 53.1 (CH₃), 42.4 (CH₂), 38.9 (CH₂), 30.3 (CH₃), 22.7 (CH₃); Ir (neat) 3332 (m), 1741 (s), 1637 (s), 1436 (w), 1407 (w), 1240 (w) cm⁻¹; HRMS (EI) m/z 293.0623 [(M+), calcd. for C₁₀H₁₆N₂O₄S₂: 293.0630].

4.7.7 2*R*-{[2*R*-Acetylamino-3-(5-nitro-pyridin-2-yl)disulfanyl]-propionyl}-methyl-amino-3-(5-nitro-pyridin-2-yl)disulfanyl}-propionic acid methyl ester (**37**)—

Compound **37** was obtained as a single conformer during the **36** to **7** transformation (see section 4.7.6). $R_f=0.34$ (EtOAc); $[\alpha]_D^{20} = -26.2$ (c 0.06, CHCl_3); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 9.31 (s, 2 H), 8.43 (d, $J = 8.7$ Hz, 2 H), 7.82 (t, $J = 8.7$ Hz, 2 H), 6.65 (d, $J = 8.7$ Hz, 1 H), 5.39 (m, 1 H), 5.05 (m, 1 H), 3.75 (s, 3 H), 3.56 (dd, $J = 14.1, 5.3$ Hz, 1 H), 3.36 (dd, $J = 13.6, 4.8$ Hz, 1 H), 3.26 (dd, $J = 13.6, 9.7$ Hz, 1 H), 3.18 (s, 3 H), 3.12 (dd, $J = 13.6, 7.8$ Hz, 1 H), 2.09 (s, 3 H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 191.2 (C), 191.0 (C), 165.9 (C), 165.3 (C), 164.3 (C), 145.7 (CH), 145.2 (CH), 141.2 (C), 139.8 (C), 131.9 (CH), 131.7 (CH), 119.9 (CH), 119.9 (CH), 63.8 (CH), 52.9 (CH), 48.4 (CH_3), 37.6 (CH_2), 29.8 (CH_2), 23.4 (CH_3), 19.6 (CH_3); Ir (neat) 3291 (br w), 3060 (w), 2925 (w), 1739 (m), 1645 (s), 1587 (s), 1563 (s), 1514 (s), 1430 (vs), 1096 (s), 1007 (w) cm^{-1} ; HRMS (EI) m/z 603.0459 [(M+), calcd. for $\text{C}_{20}\text{H}_{22}\text{N}_6\text{O}_8\text{S}_4$: 603.0460].

Compound **37** is a byproduct of the **36** to **7** transformation, but can be treated with DTT to generate **7** as follows. To a room temperature stirring solution of 13.1 mg (22.0 μmol) **37** in 20 mL DCM was added 3.4 g (22.2 μmol) dithiothreitol. After 14 h the reaction was concentrated and purified via prep-HPLC to provide 2.0 mg (32%) **7** as a white solid in a single conformer.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This study was supported by NIH grant GM070742 to RJH. ELR was supported by NIH grant PHS T32 HL07594.

References and Notes

- Hudáky I, Gáspári Z, Carugo O, Cemzar M, Pongor S, Perczel A. *Proteins: Struct., Func. Bioinf.* 2004; 55:152–168.
- Wang X-H, Connor M, Smith R, Maciejewski MW, Howden MEH, Nicholson GM, Christie MJ, King GF. *Nat. Struct. Biol.* 2000; 7:505–513. [PubMed: 10881200]
- Blake CCF, Ghosh M, Harlos K, Avezoux A, Anthony C. *Struct. Biol.* 1994; 1:102–105.
- Oubrie A, Rozeboom HJ, Kalk KH, Huizinga EG, Dijkstra BW. *J. Biol. Chem.* 2002; 277:3727–3732. [PubMed: 11714714]
- Creighton CJ, Reynolds CH, Lee DHS, Leo GC, Reitz AB. *J. Am. Chem. Soc.* 2001; 123:12664–12669. [PubMed: 11741432]
- Avizonis DZ, Farr-Jones S, Kosen PA, Basus VJ. *J. Am. Chem. Soc.* 1996; 118:13031–13039.
- Kao PN, Karlin A. *J. Biol. Chem.* 1986; 261:8085–8088. [PubMed: 3722144]
- Laakkonen L, Jobson RW, Albert VA. *Plant Biol. (Stuttg)*. 2006; 8:758–764. [PubMed: 17203431]
- Lima WF, Wu H, Nichols JG, Manalili SM, Drader JJ, Hofstadler SA, Croke ST. *J. Biol. Chem.* 2003; 278:14906–14912. [PubMed: 12473655]
- Zimmermann J, Kühne R, Sylvester M, Freund C. *Biochemistry*. 2007; 46:6971–6977. [PubMed: 17511475]
- Esposito L, De Simone A, Zagari A, Vitagliano L. *J. Mol. Biol.* 2005; 347:483–487. [PubMed: 15755444]
- Che Y, Marshall GR. *Biopolymers*. 2006; 81:392–406. [PubMed: 16358327]
- Chandrasekaran R, Balasubramanian R. *Biochim. Biophys. Acta*. 1969; 188:1–9. [PubMed: 5820682]
- Capasso S, Mattia C, Mazzarella L, Pulit R. *Acta Cryst.* 1977; B33:2080–2083.

15. Tanaka N, Ashida T, Kakudo M. *Acta Cryst.* 1977; B33:3561–3564.
16. Mez HC. *Cryst. Struct. Commun.* 1974; 3:657–660.
17. Varughese KI, Lu CT, Kartha G. *Int. J. Peptide Protein Res.* 1981; 18:88–102. [PubMed: 7309371]
18. Horne A, North M, Parkinson JA, Sadler IH. *Tetrahedron.* 1993; 49:5891–5904.
19. Fujimura K, Ito S, Suhara H, Kawashima Y. *J. Chem. Res. (S).* 1992:88–89.
20. Baxter RL, Glover SSB, Gordon EM, Gould RO, McKie MC, Scott AI, Walkinshaw MD. *J. Chem. Soc. Perkin Trans. 1.* 1988:365–371.
21. Sukumaran DK, Prorok M, Lawrence DS. *J. Am. Chem. Soc.* 1991; 113:706–707.
22. Lauth X, Babon JJ, Stannard JA, Singh S, Nizet V, Carlberg JM, Ostland VE, Pennington MW, Norton RS, Westerman ME. *J. Biol. Chem.* 2005; 280:9272–9282. [PubMed: 15546886]
23. Cumberbatch S, North M, Zagotto G. *Tetrahedron.* 1993; 49:9049–9066.
24. Lu KP, Finn G, Lee TH, Nicholson LK. *Nat. Chem. Biol.* 2007; 3:619–629. [PubMed: 17876319]
25. Moise L, Piserchio A, Basus VJ, Hawrot E. *J. Biol. Chem.* 2002; 277:12406–12417. [PubMed: 11790782]
26. Rogers DW, von Voithenberg H, Allinger NL. *J. Org. Chem.* 1978; 43:360–361.
27. Cumberbatch S, North M, Zagotto G. *J. Chem. Soc. Chem. Commun.* 1993:641–642.
28. Vitoux B, Aubry A, Cung MT, Marraud M. *Int. J. Pept. Protein Res.* 1986; 27:617–632.
29. Cepas SC, North M. *Tetrahedron.* 1997; 53:16859–16866.
30. Houk J, Whitesides GM. *J. Am. Chem. Soc.* 1987; 109:6825–6836.
31. Ruggles EL, Hondal RJ. *Tetrahedron Lett.* 2006; 47:4281–4284. [PubMed: 23828656]
32. Dobbs AP, Guesné SJJ, Martinovic S, Coles SJ, Hursthouse MB. *J. Org. Chem.* 2003; 68:7880–7883. [PubMed: 14510570]
33. Redman JE, Sanders JKM. *Org. Lett.* 2000; 2:4141–4144. [PubMed: 11150184]
34. Shah STA, Khan KM, Fecker M, Voelter W. *Tetrahedron Lett.* 2003; 44:6789–6791.
35. Rao PV, Bhaduri S, Jiang J, Holm RH. *Inorg. Chem.* 2004; 43:5833–5849. Acid 21. [PubMed: 15360232] Maltese M. *J. Org. Chem.* 2001; 66:7615–7625. Amine 22. [PubMed: 11701012]
36. Montalbetti CAGN, Falque V. *Tetrahedron.* 2005; 61:10827–10852.
37. Pearson DA, Blanchette M, Baker ML, Guindon CA. *Tetrahedron Lett.* 1989; 30:2739–2742.
38. Patel HM, Tao J, Walsh CT. *Biochemistry.* 2003; 42:10514–10527. [PubMed: 12950179]
39. Ruggles EL, Flemer SF Jr, Hondal RJ. *Biopolymers.* 2008; 90:61–68. [PubMed: 18008337]
40. Aurelio L, Box JS, Brownlee RTC, Hughes AB, Sleebs MM. *J. Org. Chem.* 2003; 68:2652–2667. [PubMed: 12662035]
41. Freidinger RM, Hinkle JS, Perlow DS, Arison BH. *J. Org. Chem.* 1983; 48:77–81.
42. Garner P, Park JM. *Organic Syntheses, Coll. Vol.* 1998; 9:300–307.
43. Greene, TW.; Wuts, PGM. *Protective Groups in Organic Synthesis* 4th Edition. New York: John Wiley & Sons; 1999. p. 711-713.
44. Han S-Y, Kim Y-A. *Tetrahedron.* 2004; 60:2447–2467.
45. Greene, TW.; Wuts, PGM. *Protective Groups in Organic Synthesis* 4th Edition. New York: John Wiley & Sons; 1999. p. 688-689.
46. Flemer SF Jr, Lacey BM, Hondal RJ. *J. Pept. Sci.* 2008; 14:637–647. [PubMed: 18035847]
47. Mossner E, Huber-Wunderluch M, Glockshuber R. *Prot. Sci.* 1998; 7:1233–1244.
48. Armarego, WLF.; Perrin, DD. *Purification of Laboratory Chemicals.* 4th ed.. Woburn, MA: Butterworth-Heinemann; 1998.
49. Perlman N, Albeck A. *Syn. Comm.* 2000; 30:4443–4449.
50. Eya BK, Otsuka T, Kubo I, Wood DL. *Tetrahedron.* 1990; 46:2695–2706.
51. Gassman PG, Bonser SM, Mlinaric-Majerski K. *J. Am. Chem. Soc.* 1989; 111:2652–2662.




Figure 1.
VDR mimics




Figure 2.
¹H-NMR thiol-disulfide equilibrium redox experiment for *cis*-dithiocine **2**




Figure 3.
Dithiazacanone VDR conformations







Figure 4.
Dipeptide VDR conformations

**Scheme 1.**


Reagents and conditions for dithiocine synthesis: (a) *m*CPBA, K₂HPO₄, DCM:H₂O; (b) 10% H₂SO₄, THF; (c) NaIO₄, THF; (d) NaBH₄, H₂O, THF; (e) DEAD, Ph₃P, AcSH, Et₂O; (f) K₂CO₃, MeOH; (g) CsF-celite, air, ACN 30 mM; (h) H₂SO₄, MeOH (97%), (i) LAH, Et₂O.

**Scheme 2.**

Reagents and conditions for dithiazacanone synthesis: (a) 4-DMAP, TrtCl, Et₃N, DMF; (b) **21**, **22**, DCC, HOBT, Et₃N, DCM:DMF; (c) TES, TFA, DCM; (d) CsF-celite, air, ACN, 1 mM; (e) NaH, MeI, DMF.

**Scheme 3.**







Reagents and conditions for dipeptide synthesis: (a) DCC, HOBT, Et₃N, DCM:DMF; (b) TES, TFA, DCM; (c) CsF-celite, air, ACN, 1 mM; (d) CSA, (CH₂O)_n, PhH, reflux; (e) TFA, TES, DCM; (f) K₂CO₃, MeI, DMF; (g) Et₂NH, DCM; (h) **27**, HATU, Hünigs, DCM; (i) DTT, NMM, DMF; (j) 1) DTNP, 2) TFA, 3) TES, DCM; (k) DTT, NMM, DCM.



Scheme 4.
Proposed Mechanism for Formation of VDR 7

Table 1

VDR redox potentials

	<i>Cisoid</i>	<i>Transoid</i>
1)	 <p>2 -318 mV</p>	 <p>18 -329 mV</p>
2)	 <p>5 -320 mV</p>	 <p>4 -278 mV</p>
3)	 <p>7 -363 mV</p>	 <p>6 -311 mV</p>